Navigation Links
Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
Date:4/29/2008

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Preliminary results were released today from a late-stage clinical trial of Rituxan (rituximab) for the treatment of lupus. The study did not meet its primary or secondary endpoints of clinically reducing the severity of SLE (systemic lupus erythematosus) in people with moderate disease.

The findings are initial results from a Phase II/III study conducted by Genentech, Inc., known as the EXPLORER study. Rituxan is approved by the U.S. Food and Drug Administration for the treatment of non-Hodgkin's lymphoma, and was more recently approved, in combination with methotrexate, to treat rheumatoid arthritis. More detailed findings from the trial are expected to be presented at a medical conference this fall.

Following is a statement about the study results from Sandra C. Raymond, President & CEO of the Lupus Foundation of America:

"Demonstrating the impact of a treatment in a lupus clinical trial can be difficult, as lupus manifests itself differently in different people, and can increase and decrease in severity from one day to another. So while these new results are disappointing, they are not necessarily surprising.

"People with lupus have been waiting for a new treatment for nearly 45 years while suffering from this disabling and sometimes life-threatening disease. But it's important to remember that there are a variety of promising therapies in the near-term pipeline - including an ongoing study of Rituxan for the treatment of lupus nephritis (kidney disease). That study assesses Rituxan's potential in a focused subset of lupus patients with a highly objective outcome. Thus, we remain optimistic that we are coming ever closer to new and better treatments for lupus.

"Lupus patients have suffered without a new treatment for more than four decades. For this reason, we are grateful to the companies that are searching for new lupus treatments. The millions of people who bat
'/>"/>

SOURCE Lupus Foundation of America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
3. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
4. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
9. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
10. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
11. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... Annual  Healthcare Conference on Thursday, May 30, 2013, at ... beginning at 9:20 a.m. Eastern Daylight Time. Arvind ... will present at the conference. Live audio of the presentation ... www.amgen.com , under Investors. A replay of the webcast ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... China, April 16, 2011 China Medical Equipment ... provider of ultrasound and MRI systems in China, ... portable ultrasound machine. The iuStar100 utilizes Samplify,s high-performance, ... SAM1600 analog to digital converter (ADC) to deliver ...
... Md., April 15, 2011 The U.S. Food and ... or in combination with methotrexate, for the treatment ... children ages 2 years and older. ... Still,s disease, is a rare, potentially life-threatening disorder ...
Cached Medicine Technology:United Imaging Healthcare Leverages Samplify's Analog Front-End Solutions to Deliver New Portable Ultrasound System with Superior Image Quality 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3
(Date:5/24/2013)... Beach, Delaware (PRWEB) May 24, 2013 ... Mushrush has joined the Dayna Feher team at the ... Mushrush made the Delaware resorts her home in 1975. ... has since worked in all aspects of the real ... and for the past 12 years, a licensed sales ...
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout ... is offering tips to help prevent grill fires throughout the ... (NFPA) reports that gas grills led to an average ... other solid-fueled grills, meanwhile, caused approximately 1,200 home fires per ... Insurance is sharing the following tips from the NFPA to ...
(Date:5/24/2013)... -- New research suggests a link between sleep ... Every additional hour someone with insomnia sleeps ... the likelihood of moderate or high risk of ... Pennsylvania. "We were surprised by the ... suicide risk," study author, Linden Oliver, clinical research ...
(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...
(Date:5/24/2013)... -- Drugs commonly used to treat glaucoma may cause ... with vision, according to a new study. The ... to reduce eye pressure, have already been shown to ... the researchers said, suggesting that the new findings could ... should be conservative when prescribing these drugs, the researchers ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2
... Safest, Most Fuel-Efficient Route and Protect Sensitive Medical Equipment as They Bring ... ... Calif. (Vocus) March 16, 2009 -- Applied Weather Technology (AWT) ... ships to deliver free, world-class health care services to the poor, recently ...
... faster by automating the admissions process with Web-based referral management software ... ... GA (PRWEB) March 16, 2009--Patient Placement System announced today the launch ... The Web-based service is an easy, low-cost software solution ...
... SHENZHEN, China, March 16 /PRNewswire-Aisia-FirstCall/ -- China Nepstar,Chain ... Nepstar" or the "Company"), the,largest drugstore chain in ... today announced that the Board of Directors has ... Share (ADS), or approximately,RMB250 million, which amounts to ...
... follows brain injury, researcher says, , , SUNDAY, March 15 ... drugs may prevent long-term damage from traumatic brain injury, ... Center researchers. , The drugs -- gamma-secretase inhibitors -- ... the brains of people with Alzheimer,s disease, according to ...
... carefully administered daily dose of peanuts has been so successful ... of children is now off treatment and eating peanuts daily, ... Hospital. , "It appears these children have lost their ... Pediatric Allergy and Immunology at Duke. "This gives other parents ...
... better than Lasik for individuals over 50. It Imparts distance and near ... cataracts, and does not induce dry eye. , ... Los Angeles, CA ... is better than Lasik for individuals over 50. It Imparts distance and ...
Cached Medicine News:Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 2Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 3Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 4Health News:Applied Weather Technology Guides Mercy Ships with Latest BVS Marine Voyage Optimization Software 5Health News:Patient Placement Systems Announces Free 30-Day Trial Program for Referral Management System 2Health News:Patient Placement Systems Announces Free 30-Day Trial Program for Referral Management System 3Health News:China Nepstar Chain Drugstore Announces Dividend 2Health News:China Nepstar Chain Drugstore Announces Dividend 3Health News:Alzheimer's Drug May Someday Help Head Trauma Victims 2Health News:Studies show children can complete treatment for peanut allergies and achieve long-term tolerance 2Health News:Studies show children can complete treatment for peanut allergies and achieve long-term tolerance 3Health News:PRELEX is the Answer for Baby Boomers Vision Needs 2
... Biosensor's compact BioStress 2000 is a software ... Stress testing system. The BioStress 2000 program ... ECG viewing, permanent ECG strorage and retrieval ... any printer. BioStress 2000 allows a wide ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
... a simple way to lift the heart ... the XPOSE 3. The XPOSE 3 is ... off-pump bypass surgery and to easily position ... Designed for both apical and non-apical placement ...
... The CLEARGLIDE Optical Vessel Dissector has ... an operative cavity in the extraperitoneal spaces ... areas. The device may be used in ... The EVH system enables harvesting of a ...
Medicine Products: